Related references
Note: Only part of the references are listed.Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S. Fuchs et al.
GASTRIC CANCER (2022)
Current treatment and recent progress in gastric cancer
Smita S. Joshi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer
Po-Chu Lee et al.
ONCOGENE (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4
Yilong Dong et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
Surgical management of advanced gastric cancer: An evolving issue
L. Marano et al.
EJSO (2016)
Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects
Neil D. Merrett
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Adjuvant therapy for gastric cancer: Current and future directions
Marcus Foo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
EphA4 is a prognostic factor in gastric cancer
Kohji Miyazaki et al.
BMC CLINICAL PATHOLOGY (2013)
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans
Annelies Van Hoecke et al.
NATURE MEDICINE (2012)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Elena B. Pasquale
NATURE REVIEWS CANCER (2010)
EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line
Junya Fukai et al.
MOLECULAR CANCER THERAPEUTICS (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers
Mariko Oki et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assembly
A Poliakov et al.
DEVELOPMENTAL CELL (2004)
ZDOCK: An initial-stage protein-docking algorithm
R Chen et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2003)
Mechanisms and functions of EPH and ephrin signalling
K Kullander et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Methods for the generation of chicken monoclonal antibody fragments by phage display
J Andris-Widhopf et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
Share Paper
